Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CDK9 | P50750 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | CDK7 | P50613 | 1/20 | 0.35 |
| ▸ | CCNH | P51946 | 1/20 | 0.35 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554942 | 0.82 | CSNK1A1 (0.40) | TP53MAPK1NPC1ALDH1A1MAPT | |
| SCHEMBL1817312 | 0.82 | CSNK1A1 (0.51) | TP53MAPK1NPC1ALDH1A1MAPT | |
| SCHEMBL25234983 | 0.80 | KDM4E (0.40) | TP53MAPK1NPC1ALDH1A1MAPT | |
| SCHEMBL21780778 | 0.76 | NPC1 (0.37) | TP53MAPK1NPC1ALDH1A1MAPT | |
| SCHEMBL15434635 | 0.74 | CSNK1A1 (0.39) | MAPK1NPC1ALDH1A1HTTNPSR1 | |
| SCHEMBL2350715 | 0.74 | MAPT (0.42) | TP53MAPK1NPC1ALDH1A1MAPT | |
| SCHEMBL5257326 | 0.73 | SYK (0.46) | ALDH1A1CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL16835367 | 0.72 | KDM4E (0.43) | TP53MAPK1NPC1ALDH1A1MAPT | |
| SCHEMBL2981824 | 0.72 | CDK1 (0.47) | TP53MAPK1NPC1ALDH1A1MAPT | |
| SCHEMBL13734423 | 0.72 | MAPK1 (0.33) | TP53MAPK1NPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3660011-A1 | BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janssen Pharmaceutica NV (BE) | 2020-06-03 | — | — | EP | disclosed |
| US-9663497-B2 | Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-30 | — | — | US | disclosed |
| US-20160340337-A1 | BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | NOVASSAY S.A. (CH) | 2016-11-24 | — | — | US | disclosed |
| US-9434715-B2 | Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-06 | — | — | US | disclosed |
| US-20160159775-A1 | BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-09 | — | — | US | disclosed |
| US-9278952-B2 | Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-08 | — | — | US | disclosed |
| CN-105025898-A | Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV | 2015-11-04 | — | — | CN | disclosed |
| US-20140364607-A1 | BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-11 | — | — | US | disclosed |
| US-8859575-B2 | Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-14 | — | — | US | disclosed |
| US-20140256942-A1 | Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor | JANSSEN PHARMACEUTICA NV (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340337-A1 | BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | TP53 3134/4885MAPK1 3089/4885NPC1 2570/4885 |
| US-20140364607-A1 | BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | TP53 3134/4885MAPK1 3089/4885NPC1 2570/4885 |
| US-20140256942-A1 | Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor | HRH4, HRH3, HRH2 | TP53 3134/4885MAPK1 3089/4885NPC1 2570/4885 |
| US-20160159775-A1 | BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | TP53 3134/4885MAPK1 3089/4885NPC1 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.